Arrowhead Pharmaceuticals (ARWR) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Grifols S.A. (GRFS) over the past year, gaining 2.3% versus a loss of 3.0%. Over five years, GRFS leads with a -25.3% price change compared with -42.6% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $5.55 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | GRFS |
|---|---|---|
| Share price | $41.37 | $8.15 |
| Market cap | $5.85B | $5.55B |
| 1-day change | -5.22% | -0.61% |
| YTD return | -37.69% | -12.83% |
| 1-year return | +2.27% | -2.98% |
| 5-year return | -42.56% | -25.30% |
| P/E ratio (TTM) | — | 9.82 |
| Forward P/E | — | 6.55 |
| EPS (TTM) | $-5.11 | $0.83 |
| Dividend yield | 0.00% | 1.30% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $450.82M | — |
| Revenue growth (YoY) | -45.65% | — |
| Net income (latest FY) | $-724.21M | — |
| Operating margin | -156.86% | — |
| Net margin | -160.64% | — |
| 52-week high | $95.49 | $9.77 |
| 52-week low | $40.43 | $6.96 |
| Distance from 52-week high | -56.68% | -16.58% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +156.39% | +27.24% |
| Average volume | 2.08M | 628.64K |
| Shares outstanding | 141.37M | 258.22M |
| Employees | 1,062 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees
ARWR vs GRFS FAQ
Which is bigger, Arrowhead Pharmaceuticals or Grifols S.A.?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $5.55B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, ARWR or GRFS?
ARWR returned +2.27% over the past 12 months, compared with -2.98% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Arrowhead Pharmaceuticals or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.30%, while Arrowhead Pharmaceuticals does not currently pay a regular dividend.
Are Arrowhead Pharmaceuticals and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.